

To,

Date: 14.02.2020

BSE Limited
P.J. Towers, Dalal Street,
Mumbai – 400 001

Metropolitan Stock Exchange of India Limited
Vibgyor Towers, 4th floor, Plot No. C62, Opp. Trident
Hotel, BandraKurla Complex, Bandra (E),
Mumbai- 400 098

Dear Sir/Madam,

Sub: Outcome of board meeting under Regulation 30 read with 33 (3) (c) of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015

Ref: (Scrip code: 539267/ DRHABEEB)

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of DrHabeebullah Life Sciences Limited held on Friday, the 14th day of February, 2020 at 03:30P.M. at the registered office of the Company, the following were considered and approved by the Board:

1. Un-Audited financial Statements (Standalone & Consolidated) for the quarter ended 31.12.2019.
2. Limited Review Report for the quarter ended 31.12.2019
3. Resignation of Ms. Kalidindi Nirusha from the post of Chief Financial Officer (CFO) of the company due to her personal commitments and preoccupations(w.e.f 14.02.2020).
4. Appointment of Mr. K.N.V Narendera Kumaras Chief Financial Officer (CFO) of the company (w.e.f. 14.02.2020).
5. Appointment of Ms. Neha Kankariya as Company Secretary and Compliance officer of the Company (w.e.f. 01.02.2020).

The meeting of the Board of Directors commenced at 03:30 P.M.(IST) and concluded at 05:45 P.M (IST).

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,
For Dr Habeebullah Life Sciences Limited


K. Krishnam Raju
Whole-Time Director
(DIN: 00874650)



Encl: as above

Dr Habeebullah Life Sciences Ltd

(Formerly Known as PC Products India Limited)

Regd. Off : 2-5-36/CLRD/1, Chintalmet X Roads, Upperpally, Rajendra Nagar Mandal, Hyderabad-500048. TS. India.

Corp Off : No.11, Phase I, Vasudeva's Bloomfield Elation, Khajaguda, Nanakramguda, Hyderabad-500008. TS. India.

CIN No.: L85110TG1996PLC099198.

Email: cs@drhsl.com, info@drhsl.com, pcproductsindia@gmail.com

Contact No.: 040 – 2970 3333, +91 9030057370.

Website : www.drhsl.com

PART-I							(Rs in Lakhs)
STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER III AND 9 MONTHS ENDED 31ST DECEMBER, 2019							
Sr.No	Particulars	Quarter ended			Year to date figures		Previous Year ended 31-03-2019
		3 Months ended 31-12-2019	Corresponding 3 months ended in previous year 31-12-2018	Preceding 3 months ended 30-09-2019	For current period ended 31-12-2019	For previous period ended 31-12-2018	
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	
I	Revenue from Operations	41.51	56.05	35.26	118.99	139.44	201.45
II	Other Income	4.98	-	5.64	10.62	-	11.05
III	Total Revenue (I+II)	46.49	56.05	40.90	129.61	139.44	212.49
IV	Expenses						
	Cost of Material Consumed	6.31	5.23	5.90	19.46	13.31	23.00
	Employee benefits expense	25.07	30.52	29.02	83.97	96.17	119.79
	Depreciation and Amortisation expense	0.24	0.09	0.24	0.71	0.28	0.94
	Other Expenses	52.23	66.34	55.15	172.52	197.14	282.31
	Total Expenses	83.85	102.18	90.31	276.66	306.90	426.05
V	Profit/(Loss) from before Exceptional Items and tax (I-IV)	(37.36)	(46.13)	(49.41)	(147.05)	(167.46)	(213.55)
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit/(Loss) before tax (V-VI)	(37.36)	(46.13)	(49.41)	(147.05)	(167.46)	(213.55)
VIII	Tax Expense:						
	Current Tax	-	-	-	-	-	-
	Deferred Tax	-	-	-	-	-	-
IX	Profit/ (Loss) for the period from Continuing operations (VII-VIII)	(37.36)	(46.13)	(49.41)	(147.05)	(167.46)	(213.55)
X	Profit/ (Loss) from discontinuing operations	-	-	-	-	-	-
XI	Tax Expense of discontinuing operations	-	-	-	-	-	-
XII	Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)	-	-	-	-	-	-
XIII	Profit/ (Loss) for the period (IX+XII)	(37.36)	(46.13)	(49.41)	(147.05)	(167.46)	(213.55)
XIV	Other Comprehensive Income						
	A) (i) Items that will not be reclassified to profit or loss						
	(ii) Income Tax related to items that will not be reclassified to profit or loss						
	B) (i) Items that will be reclassified to profit or loss						
	(ii) Income Tax relating to items that will be reclassified to profit or loss						
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)	(37.36)	(46.13)	(49.41)	(147.05)	(167.46)	(213.55)
XVI	Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each)						
	1) Basic	(0.25)	(0.38)	(0.33)			(1.75)
	2) Diluted	(0.25)	(0.32)	(0.33)	(0.99)	(0.99)	(1.62)
XVII	Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each)						
	1) Basic	-	-	-	-	-	-
	2) Diluted	-	-	-	-	-	-
XVIII	Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/- each)						
	1) Basic	(0.25)	(0.38)	(0.33)	(0.99)	(1.40)	(1.75)
	2) Diluted	(0.25)	(0.32)	(0.33)	(0.99)	(1.15)	(1.62)
XIX	Paid Up Equity Share Capital (Face Value of INR 10/- per share)	1,480.87	1221.37	1,480.87	1,480.87	1221.37	1380.87


Notes:

- The Unaudited Standalone financial results for the Quarter III and 9 months period ended 31, December 2019 were reviewed and recommended by the Audit Committee and approved by the Board of Directors at its meeting held on February 14, 2020. The Statutory Auditors have carried out the Limited Review of the Unaudited Standalone Financial Results in accordance with Regulation 33 of SEBI (LODR) Regulations, 2015).
- The Unaudited standalone financial results of the Company have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (IND AS) 34 Interim Financial Reporting prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by Securities and Exchange Board of India ("SEBI") and Regulation 33 of SEBI (LODR) Regulations, 2015 and SEBI Circular dated 05th July, 2016.
- During the half year period, the Company has converted 10,00,000 Convertible Warrants into Equity Shares to Promoters of the Company.
- From effective April 01, 2019, the Company has adopted Ind AS 116 "Leases", applied to all the lease contracts existing on April 01, 2019 using the modified retrospective method. The adoption of the standard did not have any material impact on the financial results of the company for the quarter ended December 31, 2019.
- The Company has only one reportable segment as per requirements of AS 108 "Operating Segments" i.e., Health Care Sector. Hence, the separate disclosure on Segment information is not required.
- The figures of the corresponding previous period have been regrouped/reclassified wherever necessary, to make them comparable.
- The results are also available on the website of the Company www.drhlsl.com

Place : Hyderabad
Date : February 14, 2020

For DR HABEEBULLAH LIFE SCIENCES LIMITED

K. Krishnam Raju
Executive Chairman (DIN 00874650)





MSKA
& Associates

Chartered Accountants

1101/B, Manjeera Trinity Corporate,
JNTU-Hitech City Road, Kukatpally,
Hyderabad 500072, Telangana, INDIA
Tel: +91 040 6814 2999

Independent Auditor's Review Report on unaudited quarterly and year to date financial results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

The Board of Directors

Dr Habeebullah Life Sciences Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Dr Habeebullah Life Sciences Limited ('the Company') for the quarter ended December 31, 2019 and the year to-date results for the period April 01, 2019 to December 31, 2019 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('the Regulation').
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether financial results are free of material misstatements. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone financial results prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

For MSKA & Associates

Chartered Accountants

ICAI Firm Registration No. 105047W




Ananthakrishnan G

Partner

Membership No.: 205226

UDIN: 20205226AAAAEQ7796

Place: Hyderabad

Date: February 14, 2020

PART-I		(Rs in Lakhs)			
CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER III AND 9 MONTHS ENDED 31ST DECEMBER, 2019					
S.No	Particulars	Quarter ended		Year to date figures	Previous Year ended 31-03-2019
		3 Months ended 31-12-2019	Preceding 3 months ended 30-09-2019	For period ended 31-12-2019	
		(Unaudited)	(Unaudited)	(Unaudited)	
I	Revenue from Operations	41.51	35.26	118.99	201.45
II	Other Income	4.98	5.64	10.62	11.05
III	Total Revenue (I+II)	46.49	40.90	129.61	212.49
IV	Expenses				
	Cost of Material Consumed	6.31	5.90	19.46	23.00
	Employee benefits expense	29.42	33.37	93.62	131.69
	Depreciation and Amortisation expense	0.31	0.39	0.93	1.84
	Other Expenses	52.30	55.23	172.93	290.80
	Total Expenses	88.34	94.89	286.94	447.33
V	Profit/(Loss) from before Exceptional Items and tax (I-IV)	(41.85)	(53.99)	(157.33)	(234.84)
VI	Exceptional Items	-	-	-	-
VII	Profit/(Loss) before tax (V-VI)	(41.85)	(53.99)	(157.33)	(234.84)
VIII	Tax Expense:				
	Current Tax	-	-	-	-
	Deferred Tax	-	-	-	(2.68)
IX	Profit/ (Loss) for the period from Continuing operations (VII-VIII)	(41.85)	(53.99)	(157.33)	(232.16)
X	Profit/ (Loss) from discontinuing operations	-	-	-	-
XI	Tax Expense of discontinuing operations	-	-	-	-
XII	Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)	-	-	-	-
XIII	Profit/ (Loss) for the period (IX+XII)	(41.85)	(53.99)	(157.33)	(232.16)
XIV	Other Comprehensive Income				
	A)				
	(i) Items that will not be reclassified to profit or loss				
	(ii) Income Tax related to items that will not be reclassified to profit or loss				
	B)				
	(i) Items that will be reclassified to profit or loss				
	(ii) Income Tax relating to items that will be reclassified to profit or loss				
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)	(41.85)	(53.99)	(157.33)	(232.16)
XVI	Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each)				
	1) Basic	(0.28)	(0.36)	(1.06)	(1.83)
	2) Diluted	(0.28)	(0.36)	(1.06)	(1.69)
XVII	Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each)				
	1) Basic	-	-	-	-
	2) Diluted	-	-	-	-
XVIII	Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/- each)				
	1) Basic	(0.28)	(0.36)	(1.06)	(1.83)
	2) Diluted	(0.28)	(0.36)	(1.06)	(1.69)
XIX	Paid Up Equity Share Capital (Face Value of INR 10/- per share)	1,480.87	1,480.87	1,480.87	1,380.87


Notes:

- The Unaudited consolidated financial results for the Quarter III and 9 months period ended 31, December 2019 were reviewed and recommended by the Audit Committee and approved by the Board of Directors at its meeting held on February 14, 2020. The Statutory Auditors have carried out the Limited Review of the Unaudited Consolidated Financial Results in accordance with Regulation 33 of SEBI (LODR) Regulations, 2015.
- The Unaudited consolidated financial results of the Company have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (IND AS) 34 Interim Financial Reporting prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by Securities and Exchange Board of India ("SEBI") and Regulation 33 of SEBI (LODR) Regulations, 2015 and SEBI Circular dated 05th July, 2016.
- Effective April 01, 2019, the Company has adopted Ind AS 116 "Leases", applied to all the lease contracts existing on April 01, 2019 using the modified retrospective method. The adoption of the standard did not have any material impact on the financial results of the company for the quarter ended December 31, 2019.
- The Company has only one reportable segment as per requirements of AS 108 "Operating Segments" i.e., Health Care Sector. Hence, the separate disclosure on Segment information is not required.
- The figures of the corresponding previous period have been regrouped/reclassified wherever necessary, to make them comparable.
- The corresponding previous quarter and 9 months ended figures have not been provided as they were not declared in consolidated format in previous year.
- The results are also available on the website of the Company www.drhsl.com

Place : Hyderabad
Date : 14/02/2020

For DR HABEEBULLAH LIFE SCIENCES LIMITED

K. Krishnam Raju
Executive Chairman (DIN 00874650)



Independent Auditor's Review Report on Consolidated Unaudited Quarterly and year to date financial results of the Group, its Associate and Joint Venture pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**The Board of Directors****Dr Habeebullah Life Sciences Limited**

1. We have reviewed the accompanying statement of consolidated unaudited financial results of Dr Habeebullah Life Sciences Limited ('the Holding Company'), its subsidiary, (the Holding Company and its subsidiary together referred to as the 'Group') for the quarter ended December 31, 2019 and the year to-date results for the period from April 01, 2019 to December 31, 2019 ('the Statement'), being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('the Regulation').
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

Sr. No	Name of the Company	Relationship with the Holding Company
1	Krisani Bio Sciences Private Limited	Subsidiary Company



5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review, nothing has come to our attention that cause us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

For MSKA & Associates

Chartered Accountants

ICAI Firm Registration No. 105947/W



Ananthakrishnan G

Partner

Membership No.: 205226

UDIN: 20205226AAAAER8066

Place: Hyderabad

Date: February 14, 2020